Barclays PLC Adc Therapeutics Sa Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Barclays PLC holds 141,495 shares of ADCT stock, worth $240,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141,495
Previous 127,739
10.77%
Holding current value
$240,541
Previous $402,000
29.85%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
55.3MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$26.6 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$16.2 Million5.62% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$10.1 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$6.73 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$6.04 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $132M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...